口服糖皮质激素治疗早期弥漫性系统性硬化症皮肤纤维化:欧洲硬皮病试验与研究组数据库的靶试验模拟研究
基于欧洲硬皮病试验与研究组数据库的靶试验模拟研究,纳入208例早期弥漫性皮肤型系统性硬化症患者,比较口服糖皮质激素(≤20 mg/天泼尼松等效剂量)联合免疫抑制与单用免疫抑制的疗效与安全性。结果显示12±3个月时改良Rodnan皮肤评分变化两组相似,未发现加用低剂量口服糖皮质激素对皮肤纤维化有显著获益,且该剂量未增加硬皮病肾危象风险。
要点
- 12±3个月时改良Rodnan皮肤评分变化:治疗组下降2.7(95%CI 1.4-4.0)vs 对照组下降3.1(95%CI 1.9-4.4),P=0.64。
- 治疗组中位泼尼松剂量为5 mg/天,两组所有预设次要终点均无组间差异。
- 两组各发生1例硬皮病肾危象,该剂量下未增加肾危象风险。
核心结论
- 未发现加用低剂量口服糖皮质激素对早期弥漫性皮肤型系统性硬化症皮肤纤维化有显著获益,且该剂量未增加硬皮病肾危象风险。
研究设计与样本
- 采用欧洲硬皮病试验与研究组数据库进行的靶试验模拟研究,模拟随机对照试验比较口服糖皮质激素联合免疫抑制(治疗组)与单用免疫抑制(对照组)。
- 通过倾向性评分匹配纳入208例早期弥漫性皮肤型系统性硬化症患者,每组104例,平均年龄49岁,男性33%,抗Scl-70阳性59%。
- 主要终点为基线至12±3个月改良Rodnan皮肤评分的变化;次要终点为进行性皮肤或肺纤维化及硬皮病肾危象的发生差异。
主要发现
- 12±3个月时改良Rodnan皮肤评分平均变化两组相似:治疗组下降2.7(95%CI 1.4-4.0)vs 对照组下降3.1(95%CI 1.9-4.4),P=0.64。
- 在病程较短(≤24个月)或改良Rodnan皮肤评分≤22的患者中观察到相似结果。
- 所有预设次要终点均无组间差异;两组各发生1例硬皮病肾危象。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study is to evaluate whether adding oral glucocorticoids to immunosuppressive therapy improves skin scores and ensures safety in patients with early diffuse cutaneous systemic sclerosis (dcSSc). METHODS: We performed an emulated randomized trial comparing the changes from baseline to 12 ± 3 months of the modified Rodnan skin score (mRSS: primary outcome) in patients with early dcSSc receiving either oral glucocorticoids (≤20 mg/day prednisone equivalent) combined with immunosuppression (treated) or immunosuppression alone (controls), using data from the European Scleroderma Trials and Research Group. Secondary end points were the difference occurrence of progressive skin or lung fibrosis and scleroderma renal crisis. Matching propensity score was used to adjust for baseline imbalance between groups. RESULTS: We matched 208 patients (mean age 49 years; 33% male; 59% anti-Scl70), 104 in each treatment group, obtaining comparable characteristics at baseline. In the treated group, patients received a median prednisone dose of 5 mg/day. Mean mRSS change at 12 ± 3 months was similar in the two groups (decrease of 2.7 [95% confidence interval {95% CI} 1.4-4.0] in treated vs 3.1 [95% CI 1.9-4.4] in control, P = 0.64). Similar results were observed in patients with shorter disease duration (≤ 24 months) or with mRSS ≤22. There was no between-group difference for all prespecified secondary outcomes. A case of scleroderma renal crisis occurred in both groups. CONCLUSION: We did not find any significant benefit of adding low-dose oral glucocorticoids to immunosuppression for skin fibrosis, and at this dosage, glucocorticoid did not increase the risk of scleroderma renal crisis.
引用
- Mongin D, Matucci-Cerinic M, Walker UA, et al. Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database. Arthritis Care Res (Hoboken). 2025. PMID: 39542851. doi:10.1002/acr.25469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。